Mark Capone to strengthen diagnostics platform with 35-year career in life sciences and molecular diagnostics.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Microba Life Sciences, is empowering global consumer goods company Unilever to explore links between sleep and the human gut.
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
A/Prof Krause will discuss the human-first, data-driven approach to therapeutic discovery that Microba employs in their IBD therapeutic program.
The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
Microba launched an IBD Research and Development (R&D) program in 2019 to tackle IBD by mining the gut microbiome for novel biotherapeutics.
Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).